{"nctId":"NCT00626028","briefTitle":"Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing","startDateStruct":{"date":"2004-09","type":"ACTUAL"},"conditions":["Idiopathic Pulmonary Arterial Hypertension","Cardiomyopathy"],"count":136,"armGroups":[{"label":"Nitric Oxide First, Oxygen Last","type":"EXPERIMENTAL","interventionNames":["Drug: Nitric Oxide for inhalation","Drug: Oxygen","Drug: Nitric Oxide plus Oxygen"]},{"label":"Oxygen First, Nitric Oxide Last","type":"EXPERIMENTAL","interventionNames":["Drug: Nitric Oxide for inhalation","Drug: Oxygen","Drug: Nitric Oxide plus Oxygen"]}],"interventions":[{"name":"Nitric Oxide for inhalation","otherNames":["INOmax®"]},{"name":"Oxygen","otherNames":[]},{"name":"Nitric Oxide plus Oxygen","otherNames":["Inhaled Nitric Oxide, Oxygen"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Must have any one of these three disease categories:\n\n   * Idiopathic Pulmonary Arterial Hypertension\n\n     * Mean pulmonary arterial pressure (PAPm) \\> 25 millimeters of mercury (mmHg) at rest, pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and PVRI\\> 3 u•m\\^2 or diagnosed clinically with no previous catheterization\n   * Congenital heart disease (CHD) with pulmonary hypertension repaired and unrepaired\n\n     * PAPm \\> 25 mmHg at rest and PVRI\\> 3 u•m\\^2 or diagnosed clinically with no previous catheterization\n   * Cardiomyopathy\n\n     * PAPm \\> 25 mmHg at rest and Pulmonary vascular resistance index (PVRI)\\> 3 u•m\\^2 or diagnosed clinically with no previous catheterization\n2. Scheduled to undergo right heart catheterization to assess pulmonary vasoreactivity by acute pulmonary vasodilation testing.\n3. Male or female, ages 4 weeks to 18 years, inclusive\n4. Signed informed consent/assent\n\nExclusion Criteria:\n\n1. Focal pulmonary infiltrates on chest radiograph.\n2. Diagnosed with severe obstructive or restrictive pulmonary disease that is significantly contributing to the patient's pulmonary hypertension.\n3. Received treatment with nitric oxide for inhalation within 30 days prior to study initiation, are on other investigational medications, nitroglycerin, sodium nitroprusside, sildenafil, other Phosphodiesterase type 5 (PDE-5) inhibitors, or prostacyclin\n4. Pregnant \\[urine human chorionic gonadotropin positive (HCG +)\\]\n5. Baseline Pulmonary capillary wedge pressure (PCWP) \\> 20 mmHg","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Weeks","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Reversible Pulmonary Hypertension (Vasoreactivity)","description":"A composite of hemodynamic measurements were used to identify reversible pulmonary hypertension (vasoreactivity)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Related Surgical Procedures Within 1 Year","description":"Number of participants who received surgery for pulmonary or cardiac disease within 1 year after treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"An AE was defined as any untoward medical occurrence. An AE need not have a causal relationship with treatment and included any event that was not seen at baseline or, if present at baseline, increased in severity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"SAEs were collected during the 12 hours after discontinuation of gas or discharge (whichever came first). An SAE was defined as any event that resulted in death, was life threatening, resulted in permanent disability or incapacity, required or prolonged inpatient hospitalization, or was a congenital anomaly. Important medical events that, without medical or surgical intervention, would also have resulted in one of the outcomes listed above were also considered as SAEs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Related Surgical Procedures Within 3 Years","description":"Number of participants who received surgery related to pulmonary or cardiac disease within 3 years","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":62},"commonTop":[]}}}